These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 24081217

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats.
    Sharma AK, Kanawat DS, Mishra A, Dhakad PK, Sharma P, Srivastava V, Joshi S, Joshi M, Raikwar SK, Kurmi MK, Srinivasan BP.
    J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):410-8. PubMed ID: 23396552
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Changes in body weight after 24 weeks of vildagliptin therapy as a function of fasting glucose levels in patients with type 2 diabetes.
    Blüher M, Schweizer A, Bader G, Foley JE.
    Vasc Health Risk Manag; 2014 Dec; 10():661-4. PubMed ID: 25429228
    [Abstract] [Full Text] [Related]

  • 6. Dipeptidyl peptidase 4 inhibition and vildagliptin therapy for type 2 diabetes.
    Del Prato S.
    Int J Clin Pract Suppl; 2007 Aug; (154):38-48. PubMed ID: 17593276
    [Abstract] [Full Text] [Related]

  • 7. Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.
    Kodera R, Shikata K, Takatsuka T, Oda K, Miyamoto S, Kajitani N, Hirota D, Ono T, Usui HK, Makino H.
    Biochem Biophys Res Commun; 2014 Jan 17; 443(3):828-33. PubMed ID: 24342619
    [Abstract] [Full Text] [Related]

  • 8. The efficacy and safety of vildagliptin in patients with type 2 diabetes: a meta-analysis of randomized clinical trials.
    Cai L, Cai Y, Lu ZJ, Zhang Y, Liu P.
    J Clin Pharm Ther; 2012 Aug 17; 37(4):386-98. PubMed ID: 22191695
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients.
    Bunck MC, Poelma M, Eekhoff EM, Schweizer A, Heine RJ, Nijpels G, Foley JE, Diamant M.
    J Diabetes; 2012 Jun 17; 4(2):181-5. PubMed ID: 22051153
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Vildagliptin inhibits oxidative stress and vascular damage in streptozotocin-induced diabetic rats.
    Maeda S, Matsui T, Yamagishi S.
    Int J Cardiol; 2012 Jun 28; 158(1):171-3. PubMed ID: 22564388
    [No Abstract] [Full Text] [Related]

  • 15. Relationships between the islets blood flow, nitric oxide, insulin, and cytosolic calcium in rat pancreatic islets: effects of DPP-IV inhibitor vildagliptin.
    Akarte AS, Srinivasan BP, Gandhi S.
    Eur J Pharm Sci; 2012 Apr 11; 45(5):546-51. PubMed ID: 22155545
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond.
    Panina G.
    Diabetes Obes Metab; 2007 Sep 11; 9 Suppl 1():32-9. PubMed ID: 17877545
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.